JUVENTAS
Juventas is a provider and developer of innovative immune cell therapeutic drugs. The company's first investigational new drug application for the cell therapeutic product CNCT19 has been officially accepted by the National Medical Products Administration. Comprehensive product pipelines will be developed and promoted constantly to provide effective treatment for malignant hematological neoplasms such as leukemia and lymphoma.
JUVENTAS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2018-01-01
Address:
Chaoyang, Liaoning, China
Country:
China
Website Url:
http://www.juventas.cn
Total Employee:
11+
Status:
Active
Contact:
010-65960098
Email Addresses:
[email protected]
Total Funding:
101.57 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Mobile Non Scaleable Content Nginx Microsoft Azure DNS PHP PHP 7 Apple Mobile Web App Capable Apple Mobile Web App Status Bar Style
Current Employees Featured
Founder
Investors List
Ding Xiang Capital
Ding Xiang Capital investment in Series C - Juventas
Dalton Venture
Dalton Venture investment in Series C - Juventas
Delian Capital
Delian Capital investment in Series C - Juventas
CICC
CICC investment in Series C - Juventas
Redhill Capital
Redhill Capital investment in Series C - Juventas
Jiadao Capital
Jiadao Capital investment in Series C - Juventas
Haisong Capital
Haisong Capital investment in Series C - Juventas
Tianchuang Zhixing (Beijing) Touzi Guanli Zixun Youxian Gongsi
Tianchuang Zhixing (Beijing) Touzi Guanli Zixun Youxian Gongsi investment in Series C - Juventas
Tianjin Venture Capital
Tianjin Venture Capital investment in Venture Round - Juventas
CASI Pharmaceuticals
CASI Pharmaceuticals investment in Series A - Juventas
More informations about "Juventas"
Juventas - Home
Founded in June 2018, Juventas Cell Therapy Ltd. is a biopharmaceutical company focusing on the R&D and commercialization of innovative drugs such as immune cell therapy, which has in …See details»
合源生物科技（天津）有限公司 - 首页
2024-11-07 源瑞达®(纳基奥仑赛注射液)获澳门特别行政区政府药物监督管理局批准上市 ; 2024-10-11 合源生物源瑞达®新增自身免疫性疾病适应症新药临床试验（ind）申请获默示许可 ; …See details»
juventas.cn
合源生物cnct19细胞注射液是具有自主知识产权的针对cd19靶点的car-t细胞治疗产品。用于治疗复发或难治性急性淋巴细胞白血病以及复发或难治性侵袭性b细胞非霍奇金淋巴瘤。See details»
Juventas - Crunchbase Company Profile & Funding
Juventas is a provider and developer of innovative immune cell therapeutic drugs. The company's first investigational new drug application for the cell …See details»
Juventas Company Profile | Management and Employees List
Juventas Profile and History. Juventas Cell Therapy Ltd. is a China-based domestic biopharmaceutical company established in 2018 focused on clinical translation and …See details»
Juventas Cell Therapy Corp. - LinkedIn
Juventas Cell Therapy Corp. | 317 followers on LinkedIn. 合源生物科技（天津）有限公司创立于2018年6月，是一家专注于免疫细胞治疗等创新型药物研发和商业化 ...See details»
Juventas Cell Therapy Announces the Approval of Its First Cell …
Nov 10, 2023 Beijing, China and Tianjin, China and Shanghai, China--(Newsfile Corp. - November 10, 2023) - Juventas Cell Therapy Ltd. announces China National Medical Product …See details»
Juventas Cell Therapy Ltd. (合源生物科技（天津）有限 …
了解Juventas Cell Therapy Ltd. (合源生物科技（天津）有限公司)公司的药物管线，治疗领域，技术平台，以及它的32项临床试验, 343篇新闻和5篇文献，疾病领域:肿瘤，血液及淋巴系统疾病，免疫系统疾病，技术平台:通用型CAR-T，自 …See details»
Juventas Company Profile - Office Locations, Competitors ... - Craft
Juventas Cell Therapy (合源生物) is a biopharmaceutical company focused on research and development of immune cell therapy products. It provides treatments for acute lymphoblastic …See details»
Shanghai Juvensis Therapeutics Biotechnology - VentureRadar
Juventas Cell Therapy Ltd. is a biopharmaceutical company focusing on the R&D and commercialization of innovative drugs such as immune cell therapy, which has in-depth …See details»
WuXi Advanced Therapies Supports First …
SHANGHAI, November 8, 2023 – WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO) congratulates its customer, Juventas Cell Therapy, on achieving China’s …See details»
Juventas Cell Therapy Corp. Research by SuperAGI
```report ## **Company Overview** Juventas Cell Therapy Corp., founded in June 2018 and headquartered in China, is a pioneering biopharmaceutical company. The organization is …See details»
Juventas - Overview, News & Similar companies | ZoomInfo.com
Dec 4, 2019 Juventas contact info: Phone number: +86 1065960098 Website: www.juventas.cn What does Juventas do? Juventas Cell Therapy Ltd. is a China-based domestic …See details»
Juventas Cell Therapy Announces the Approval of Its First
Nov 10, 2023 About Juventas. Established in June 2018, Juventas Cell Therapy Ltd, a biopharmaceutical company powered by cutting-edge cell and gene technologies, has become …See details»
创新支付 - 合源生物科技（天津）有限公司 - juventas.cn
合源生物. 合源生物积极打造多元化创新支付路径，开展与地方政府、各级医院、基金会、以及保险公司的多方合作，以患者为中心，提升car-t药品可及性。See details»
Juventas Cell Therapy Ltd. - CMOCRO - Domain Name
Juventas is a biopharmaceutical company dedicated to the development and commercialization of cell therapies globally. Utilizing innovative and integrated technology platforms, the company …See details»
Investee Company: Juventas has raked in over 400 million yuan in …
Jul 12, 2021 Founded in June 2018, Juventas Cell Therapy Ltd. is a biomedical enterprise focusing on the R&D and commercialization of innovative drugs such as immune cell therapy, …See details»
Juventas Lands ￥400 Million Series C Funding - vbdata.cn
(VCBeat) July. 12, 2021 -- Juventas Cell Therapy Ltd. ("Juventas") today announced the closing of a Series C financing of over 400 million RMB. This round of financing was jointly led by …See details»
Juventas Cell Therapy Announces the Approval of Its First Cell …
Nov 10, 2023 BEIJING, TIANJIN, SHANGHAI, China., - NOVEMBER 10, 2023- Juventas Cell Therapy Ltd. announces China National Medical Product Administration (NMPA) has approved …See details»
Juventas Cell Therapy Ltd. Closes Series C Financing to Advance …
Jul 20, 2021 Juventas builds profound cooperation with China's leading hospitals and clinical research institutes and is committed to constructing a preeminent platform for cell therapy …See details»